



Aalborg Universitet

AALBORG UNIVERSITY  
DENMARK

## Patient selection for proton therapy of early breast cancer - the DBCG phase II study strategy

Stick, L.B.; Lorenzen, E.L.; Yates, E.S.; Anandadas, C.; Andersen, K.; Aristei, C.; Byrne, O.; Hoi, S.; Jensen, I.; Kirby, A.; Kirova, Y.M.; Marrazzo, L.; Matías-Pérez, A.; Nielsen, M.M.B.; Nissen, H.D.; Oliveros, S.; Verhoeven, K.; Vikström, J.; Offersen, B.V.

*Published in:*  
Radiotherapy and Oncology

*DOI (link to publication from Publisher):*  
[10.1016/S0167-8140\(19\)30466-9](https://doi.org/10.1016/S0167-8140(19)30466-9)

*Creative Commons License*  
CC BY-NC-ND 4.0

*Publication date:*  
2019

*Document Version*  
Publisher's PDF, also known as Version of record

[Link to publication from Aalborg University](#)

### *Citation for published version (APA):*

Stick, L. B., Lorenzen, E. L., Yates, E. S., Anandadas, C., Andersen, K., Aristei, C., Byrne, O., Hoi, S., Jensen, I., Kirby, A., Kirova, Y. M., Marrazzo, L., Matías-Pérez, A., Nielsen, M. M. B., Nissen, H. D., Oliveros, S., Verhoeven, K., Vikström, J., & Offersen, B. V. (2019). Patient selection for proton therapy of early breast cancer - the DBCG phase II study strategy. *Radiotherapy and Oncology*, 133(Suppl. 1), S15-S17. [PV-0046]. [https://doi.org/10.1016/S0167-8140\(19\)30466-9](https://doi.org/10.1016/S0167-8140(19)30466-9)

### General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal -

<sup>1</sup>LMU Munich, Department of Radiation Oncology, Munich, Germany ; <sup>2</sup>Medical University, Department of Radiation Oncology, Innsbruck, Austria ; <sup>3</sup>Hospital Sacro Cuore Don Calabria, Department of Radiation Oncology, Negrar, Italy ; <sup>4</sup>University of Brescia, Radiation Oncology, Brescia, Italy; <sup>5</sup>Red Cross Hospital, Breast Centre, Munich, Germany; <sup>6</sup>LMU Munich, Department of Obstetrics and Gynecology- Breast Centre, Munich, Germany

### Purpose or Objective

Treatment of early stage breast cancer (BC) can be considered as a preference-sensitive care, where decision-making between treatment options can vary according to patient preferences. Typical factors that influence therapy choice in favour of mastectomy include: concerns about cancer recurrence or perceived consequences related to breast conserving surgery (BCT), including potential adverse effects of radiation therapy. Aim of the present study was to compare the oncologic outcome of mastectomy versus breast conserving therapy in patients treated in a modern clinical setting outside of clinical trials.

### Material and Methods

Data were provided by the population-based Munich Cancer Registry. Between 1998 and 2014, all female patients diagnosed with early invasive BC (pT1pN0, pT2pN0, pT1pN1 and pT2pN1) and treated at two Breast Care Centres were included in this observational study. For comparison of the standard BCT and mastectomy approaches, we excluded patients with more than 3 positive lymph nodes (pN2) as postmastectomy RT (PMRT) would have been routinely recommended in these high-risk patients.

### Results

The final study cohort consisted of 7565 women with a median follow-up of 95.2 months. After adjusting for age, tumour characteristics and therapies, Cox regression analysis for local recurrence-free survival identified BCS with RT as an independent predictor for improved local control (hazard ratio [HR], 1.476; 95% confidence interval [CI], 1.164-1.872,  $p < 0.001$ ) as compared to mastectomy without RT. Ten-year risk of local recurrences was 8.7% following BCS, compared to 14.8% in patients receiving mastectomy ( $p < 0.001$ ). Similarly, lymph node recurrences (10y LNR 2.4% vs 6.7%,  $p < 0.001$ ) and distant metastasis (10y DM 9.8% vs 15.2%,  $p < 0.001$ ) were more frequent in patients undergoing mastectomy only. This translated into an improved survival outcome among patients treated with BCS plus radiotherapy (10-year OS estimates 86.7% vs 77.6%,  $p < 0.001$ ), which was also significant on multivariate analysis ( $p = 0.011$ ).

### Conclusion

In conclusion, the present study showed that patients treated with BCS followed by radiotherapy in clinical practice had an improved outcome regarding local control, distant control and overall survival as compared to mastectomy alone in a large cohort reflecting "real-life" clinical practice in this setting.

### PV-0045 Is proton therapy a "pro" for breast cancer? A comparison of proton vs. non-proton RT using the NCDB

M. Chowdhary<sup>1</sup>, A. Lee<sup>2</sup>, S. Gao<sup>3</sup>, P. Barry<sup>1</sup>, R. Diaz<sup>4</sup>, N. Bagadiya<sup>5</sup>, H. Park<sup>3</sup>, J. Yu<sup>3</sup>, L. Wilson<sup>3</sup>, M. Moran<sup>3</sup>, S. Higgins<sup>3</sup>, C. Knowlton<sup>3</sup>, K. Patel<sup>3</sup>

<sup>1</sup>Rush University Medical Center, Radiation Oncology, Chicago, USA; <sup>2</sup>SUNY Downstate Medical Center, Radiation Oncology, Brooklyn, USA; <sup>3</sup>Yale School of Medicine, Therapeutic Radiology, New Haven, USA; <sup>4</sup>Moffitt Cancer Center, Radiation Oncology, Tampa, USA; <sup>5</sup>Emory University School of Medicine, Radiology, Atlanta, USA

### Purpose or Objective

There is limited data demonstrating the clinical benefit of proton radiotherapy (PRT) in breast cancer. Here we investigate the impact of PRT on overall survival (OS) and evaluate predictors associated with PRT use for patients with breast cancer in the National Cancer Database (NCDB).

### Material and Methods

Women with non-metastatic breast cancer treated with adjuvant radiotherapy from 2004-2014 were identified using the NCDB. Patients were stratified based on receipt of PRT or non-PRT (i.e. photons +/- electrons). A logistic regression model was used to determine predictors for PRT utilization. For OS, Multivariable analysis (MVA) was performed using Cox proportional hazard model. Subset analyses were performed for groups at risk for receiving higher heart dose.

### Results

A total of 724,492 women were identified: 871 received PRT and 723,621 received non-PRT. 58.3% of the PRT patients were group stage 0-1. Median follow-up time was 62.2 months. On multivariate logistic analysis, the following factors were found to be significant for receipt of PRT (all  $p < 0.05$ ): academic facility (odds ratio [OR]=2.50), South (OR=2.01) and West location (OR=12.43), left-sided (OR=1.21), ER-positive (OR=1.59), and mastectomy (OR=1.47); pT2-T4 disease predicted for decrease PRT use (OR=0.79).

PRT was not associated with OS on MVA for all patients: Hazard Ratio: 0.85,  $p = 0.168$ . PRT remained not significant on MVA after stratifying for subsets likely associated with higher heart radiation doses, including: left-sided ( $p = 0.140$ ), inner-quadrant ( $p = 0.173$ ), mastectomy ( $p = 0.095$ ), node positivity ( $p = 0.680$ ), N2-N3 disease ( $p = 0.880$ ), and lymph node irradiation (LNI) ( $p = 0.767$ ).

### Conclusion

In this large national multicenter database, we found receipt of PRT to be associated with left-sided, ER+ tumors, mastectomy, South and West location, and academic facilities, but not higher group stages or LNI. PRT was not associated with OS, including in subsets likely at risk for higher heart doses.

In light of the high cost of proton RT, these data question the utilization of PRT, especially in early-stage patients with expected low heart doses, unless enrolled on a clinical trial.

### PV-0046 Patient selection for proton therapy of early breast cancer - the DBCG phase II study strategy

L.B. Stic<sup>1</sup>, E.L. Lorenzen<sup>2</sup>, E.S. Yates<sup>3</sup>, C. Anandadas<sup>4</sup>, K. Andersen<sup>5</sup>, C. Aristei<sup>6</sup>, O. Byrne<sup>7</sup>, S. Hol<sup>8</sup>, I. Jensen<sup>9</sup>, A. Kirby<sup>10</sup>, Y.M. Kirova<sup>11</sup>, L. Marrazzo<sup>12</sup>, A. Matias-Pérez<sup>13</sup>, M.M.B. Nielsen<sup>14</sup>, H.D. Nissen<sup>15</sup>, S. Oliveros<sup>16</sup>, K. Verhoeven<sup>17</sup>, J. Vikström<sup>18</sup>, B.V. Offersten<sup>19</sup>

<sup>1</sup>Rigshospitalet, Department of Oncology, Copenhagen, Denmark; <sup>2</sup>Odense University Hospital, Laboratory of Radiation Physics, Odense, Denmark; <sup>3</sup>Aarhus University Hospital, Department of Medical Physics, Aarhus, Denmark; <sup>4</sup>The Christie Hospital NHS Foundation Trust, Department of Clinical Oncology, Manchester, United Kingdom; <sup>5</sup>Herlev & Gentofte Hospital, Department of Radiotherapy, Herlev, Denmark; <sup>6</sup>University of Perugia & Perugia General Hospital, Department of Surgical and Biomedical Science, Perugia, Italy; <sup>7</sup>Addenbrooke's Hospital - Cambridge University Hospitals NHS Foundation Trust, Department of Medical Physics, Cambridge, United Kingdom; <sup>8</sup>Institute Verbeeten, Department of Radiation Oncology, Tilburg, The Netherlands; <sup>9</sup>Aalborg University Hospital, Department of Medical Physics, Aalborg, Denmark; <sup>10</sup>The Royal Marsden Hospital NHS Foundation Trust and Institute of Cancer Research, Department of Radiotherapy, London, United Kingdom; <sup>11</sup>Institut Curie, Department of Radiation Oncology, Paris, France; <sup>12</sup>Careggi University Hospital, Department of Medical Physics, Florence, Italy;

<sup>13</sup>Institut Gustave Roussy, Département de Radiothérapie, Villejuif, France; <sup>14</sup>Zealand University Hospital, Department of Oncology, Næstved, Denmark; <sup>15</sup>Vejle Sygehus, Department of Oncology, Vejle, Denmark; <sup>16</sup>Oxford University Hospitals NHS Foundation Trust, Department of Oncology, Oxford, United Kingdom; <sup>17</sup>Maastricht Clinic - GROW School for Oncology and Developmental Biology - Maastricht University Medical Centre, Department of Radiation Oncology, Maastricht, The Netherlands; <sup>18</sup>Stavanger University Hospital, Department of Radiotherapy, Stavanger, Norway; <sup>19</sup>Aarhus University Hospital, Department of Experimental Clinical Oncology and Department of Oncology, Aarhus, Denmark

### Purpose or Objective

Recently, overall survival gain from radiation therapy (RT) of the internal mammary nodes (IMN) was documented. IMN RT inevitably leads to more radiation dose to heart and lungs, thus often target coverage is compromised to meet constraints for doses to organs at risk (OAR). Here, doses to heart and lung are estimated when target coverage is not compromised in consecutive high-risk breast cancer (BC) patients. The aim is to establish dose cut-off points for selection of patients for proton therapy (PT) in the Danish Breast Cancer Group (DBCG) single-arm phase II trial.

### Material and Methods

179 BC patients treated with adjuvant loco-regional RT including the IMN from 18 European departments were included in the study. Each department included 5 patients with left-sided and 5 patients with right-sided BC. The prescription dose ranged from 39.9 Gy to 51.52 Gy in 15 to 28 fractions. Planning techniques included both conformal and several inversely optimized techniques (see Table 1). If the clinically delivered treatment plan did not comply with defined target coverage requirements, the plan was modified retrospectively for this study until sufficient target coverage was reached by allowing OAR constraints to be exceeded. Sufficient target coverage was in this study defined as: V90%  $\geq$  95% of CTV\_IMN, V90%  $\geq$  95% of CTVn and V95%  $\geq$  95% of CTVp\_breast/chest wall.

**Table 1** Treatment characteristics

	n (%)
Dose-fractionation scheme	
50 Gy in 25 fractions*	69 (39%)
40 Gy in 15 fractions**	101 (56%)
Other fractionation schemes	9 (5%)
Treatment technique	
3DCRT	90 (50%)
VMAT	26 (15%)
Hybrid	17 (9%)
Intensity modulated tomotherapy	35 (20%)
Step & shoot IMRT + static SCF	11 (6%)
Breath hold	
Yes	112 (63%)
No	67 (37%)
Modified plan	
Yes	71 (40%)
No	108 (60%)
Surgery	
Lumpectomy	65 (36%)
Mastectomy	95 (53%)
Reconstruction	19 (11%)
Simultaneous integrated boost	
Yes	12 (7%)
No	167 (93%)
No. of intercostal spaces in IMN target	
2	1 (<1%)
3	105 (59%)
4	71 (40%)
5	2 (1%)

Abbreviations: 3DCRT, 3D conformal radiotherapy; VMAT, volumetric modulated arc therapy; IMRT, intensity modulated radiotherapy; SCF, supraclavicular field; IMN, internal mammary nodes. \*Including patients receiving 51.52 Gy in 28 fractions (n=3). \*\*Including patients receiving 42.3 Gy in 18 fractions (n=2).

### Results

Forty percent of the treatment plans needed modification to fulfil the required dose for target coverage. Median mean heart dose (MHD) was 3.0 Gy (range, 1.1-8.2 Gy) for left-sided BC and 1.4 Gy (range, 0.4-11.5 Gy) for right-sided BC. For left-sided BC patients the median MHD was 2.8 Gy (range, 1.1-7.4 Gy) when breath hold (BH) was used (71%) and 5.2 Gy (range, 2.2-8.2 Gy) when no BH was used (29%). Median mean (ipsilateral) lung dose was 13.4 Gy (range, 5.1-24.9 Gy). Median V17Gy/V20Gy (hypofractionated/normofractionated plans) for lung was 31% (range, 0-57%). To guide selection criteria for referral to PT, we chose to set cut-off points for dose to OAR for departments that aimed for treating all patients with 3DCRT and in BH, which 9 departments did (98% 3DCRT and 93% BH). We chose MHD  $\geq$  4 Gy or lung V17Gy/V20Gy  $\geq$  37% as cut-off points for the PT study based on dose-response relationships for ischemic heart disease and radiation pneumonitis in combination with capacity limitations for PT. In the departments having 3DCRT and BH as standard, 22% of the patients had a MHD  $\geq$  4 Gy or lung V17Gy/V20Gy  $\geq$  37%. The remaining 9 departments mainly used inverse techniques (98%) where BH was used in 31% of the patients. Fifty-two percent of these patients had a MHD  $\geq$  4 Gy or lung V17Gy/V20Gy  $\geq$  37%.




Figure 1: Upper panels show heart and lung dose metrics for 3DCRT (purple circles) and inverse treatment techniques (yellow circles). Lower panels show heart and lung dose metrics for breath hold (BH, green circles) and no breath hold (blue circles). The dashed lines represent the mean heart dose  $\geq 4$  Gy and lung V17Gy/V20Gy  $\geq 37\%$  thresholds.

### Conclusion

Using thresholds of MHD  $\geq 4$  Gy and lung V17Gy/V20Gy  $\geq 37\%$  in departments using 3DCRT and BH, we estimate that 22% of all the patients requiring loco-regional IMN RT will be eligible for the DBCG phase II PT study.

### PV-0047 IMRT versus VMAT for elderly patients with breast cancer: comparison of acute and late toxicities

F. Alongi<sup>1,2</sup>, F. Gregucci<sup>1</sup>, A. Fiorentino<sup>1</sup>, R. Mazzola<sup>1</sup>, V. Figlia<sup>1</sup>, F. Ricchetti<sup>1</sup>, G. Sicignano<sup>1</sup>, N. Gaj-Levra<sup>1</sup>, S. Naccarato<sup>1</sup>, A. Massocco<sup>1</sup>, S. Corradini<sup>3</sup>, R. Ruggieri<sup>1</sup>  
<sup>1</sup>Hospital Sacro Cuore Don Calabria- Cancer Care Center, Radiation Oncology, Negrar, Italy; <sup>2</sup>University of Brescia, Radiation Oncology, Brescia, Italy; <sup>3</sup>LMU University Hospital, Radiation Oncology, Munich, Germany

### Purpose or Objective

To evaluate the differences between conventional fractionated intensity modulated radiotherapy (cIMRT) and hypofractionated (HypoRT) volumetric modulated arc therapy (VMAT) in elderly women affected by early stage Breast Cancer (BC) in terms of RT-related acute and late side effect.

### Material and Methods

Between October 2011 and July 2015, 80 consecutive elderly BC patients were treated with cIMRT for 5 weeks (40 patients) or HypoRT-VMAT for 3 weeks (40 patients). Inclusion criteria were: age  $\geq 70$  years, early stage BC (pT1-2 pN0-1), no prior neoadjuvant chemotherapy and non-metastatic disease. For patients receiving cIMRT or HypoRT-VMAT, a total dose of 50 Gy (25 fractions) or 40.5 Gy (15 fractions) were prescribed to the whole ipsilateral breast, respectively. All patients received a simultaneously integrated boost (SIB) up to a total dose of 60 Gy for cIMRT and 48 Gy for HypoRT-VMAT. Acute and late side effects were evaluated using the RTOG/EORTC radiation morbidity scoring system.

### Results

Median follow-up was 45 months. Compliance to treatment was 100% for each RT schedule, without any interruptions. The median age was 75 years (range 70-83). The median PTV breast was 929 cc (range 330-2527). In each group, 90% and 92% of patients received hormone-therapy, respectively. During RT delivery, only low grade acute skin toxicity was observed, with an advantage for

the HypoRT-VMAT group: grade 1 in 25 cases (62.5%) of the cIMRT group and 21 cases (52.5%) of the HypoRT-VMAT group ( $p=0.2$ ); while grade 2 toxicity was reported in 10 cIMRT patients (25%) and 1 HypoRT-VMAT patient (2.5%) ( $p=0.001$ ). No skin G3 or other side effects were observed at all. Regarding late adverse events, skin toxicity was overall mild without any grade 2 or higher toxicity, but resulted in significantly better outcome for patients treated with HypoRT-VMAT. Grade 1 side effects were reported in 13 cases (32.5%) of the cIMRT group as compared to 2 cases (5%) of the VMAT group ( $p=0.001$ ). G1 fibrosis was registered in 4 cIMRT (10%) cases and 2 HypoRT-VMAT patients (5%) ( $p=0.4$ ). No other late toxicities (e.g. pulmonary or arm edema) were observed. In patients treated with cIMRT, only the breast volume  $>700$  cc was statistically associated with acute G2 skin adverse events ( $p=0.04$ ). In patients receiving Hypo-RT, factors like age or breast volume did not have any influence on the onset of acute or late skin toxicity. No differences in fatigue were observed for the two groups of treatment groups: 11 cIMRT patients vs 16 HypoRT-VMAT ( $p=0.1$ ).

### Conclusion

The present study showed that whole breast cIMRT and HypoRT-VMAT are feasible and well tolerated in early stage BC elderly patients and that HypoRT-VMAT is affected by lower risk of acute and late RT-related side effects.

### PV-0048 The Radiosensitivity Index (RSI) predicts for outcomes in triple negative breast cancer

C. Liveringhouse<sup>1</sup>, N.B. Figura<sup>2</sup>, K.A. Ahmed<sup>2</sup>, G.D. Grass<sup>2</sup>, P. Blumencranz<sup>3</sup>, K. Allen<sup>3</sup>, C. Laronga<sup>4</sup>, M.C. Lee<sup>4</sup>, L.B. Harrison<sup>2</sup>, T.J. Robinson<sup>2</sup>, J.F. Torres-Roca<sup>2</sup>, R. Diaz<sup>2</sup>

<sup>1</sup>University of South Florida, Morsani College of Medicine, Tampa, USA; <sup>2</sup>Moffitt Cancer Center, Department of Radiation Oncology, Tampa, USA; <sup>3</sup>Baycare Morton Plant Hospital, Department of Breast Oncology Surgery, Clearwater, USA; <sup>4</sup>Moffitt Cancer Center, Department of Breast Oncology, Tampa, USA

### Purpose or Objective

While genomic biomarkers have been utilized to predict outcomes in ER+ breast cancer, further investigation is needed to develop similar predictors for triple negative breast cancer (TNBC). RSI is a previously validated multi-gene expression index that is thought to be radiotherapy (RT)-specific. Here, we evaluate whether RSI is an RT-specific predictive biomarker in TNBC.

### Material and Methods

Prospectively gathered breast tumor samples were identified from an IRB-approved tissue biorepository representing one academic and two community hospitals. Gene expression of tumor samples was assessed with Affymetrix microarray chips and the RSI 10-gene signature was calculated for each sample using the previously published rank-based algorithm. As in prior studies, radiophenotype was determined by dichotomizing at  $RSI=0.3745$ , where  $RSI \geq 0.3745$  is radioresistant (RR) and  $RSI < 0.3745$  is radiosensitive (RS). Clinical information was obtained by chart review. Endpoints were locoregional recurrence-free survival (LRRFS), distant metastasis-free survival (DMFS), overall survival (OS), and progression-free survival (PFS). Outcomes were estimated with Kaplan Meier (KM) methods and compared with log-rank tests. Associations between characteristics and outcomes were explored with univariable (UVA) and multivariable (MVA) Cox regression.

### Results

97 TNBC tumors with available genomic profiling were identified for analysis. The median age was 55 years (range 25-82). 97.9% of tumors were pT1-T2, and 37.1% had positive lymph nodes. 80% of tumors were high grade. 40.2% were treated with mastectomy alone, 14.4% with